{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-119406","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.243543+00:00","generated_at":"2026-05-21T10:28:53.442443+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"confidence":"high","headline":"IO Biotech Q1 net loss $22.4M; Phase 3 melanoma vaccine readout on track for Q3 2025","bullets":["Net loss of $22.4M in Q1 2025 vs $19.5M in Q1 2024; R&D expenses rose to $16.4M.","Cash and equivalents $37.1M at March 31, 2025, down from $60.0M at Dec 31, 2024; Q1 cash burn $22.9M.","Drew €10.0M tranche A of EIB loan on May 6; believes conditions met for €12.5M second tranche.","Phase 3 trial primary endpoint (PFS) readout on track for Q3 2025; BLA submission planned in 2025.","Enrollment completed in Phase 2 basket trial (IOB-032) for SCCHN/melanoma; initial data expected H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-119406","json":"https://secwatch.observer/filing/0001193125-25-119406.json","markdown":"https://secwatch.observer/filing/0001193125-25-119406.md","text":"https://secwatch.observer/filing/0001193125-25-119406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312525119406/0001193125-25-119406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312525119406/d859516d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T10:28:53.442443+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}